Related Experiment Video
Updated: Sep 3, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
MEASLES AND MEASLES VACCINATION IN AN AFRICAN VILLAGE
Abstract:
Over the last five years, a number of reports have appeared drawing attention to the serious results of measles in young West African children. This is borne out by observations over a three-year period on children in the village of Imesi, which showed measles to be a severe and often fatal disease. The original live attenuated measles vaccine developed by Enders has been shown to give good protection and, in combination with immune serum, has been widely used in the USA. However, the need to combine it with immune serum severely limits its usefulness, owing to the small quantities of serum available and the high cost. In the present study, the reaction produced by the original vaccine with immune serum was compared with the reaction produced by a further attenuated vaccine without serum. The latter gave significantly fewer and less severe reactions, but produced a satisfactory serological response. This new vaccine should facilitate large-scale immunization of children in areas such as West Africa where protection against measles is urgently required.
Insights
A new, further attenuated measles vaccine shows promise for West African children. This improved vaccine offers satisfactory protection without immune serum, reducing side effects and improving accessibility for widespread measles immunization.
Area of Science:
- Pediatrics
- Infectious Diseases
- Vaccinology
Background:
- Measles poses severe and fatal risks to young children in West Africa.
- The original Enders measles vaccine, while protective, requires immune serum, limiting its use due to availability and cost.
- There is an urgent need for effective and accessible measles immunization in regions like West Africa.
Purpose of the Study:
- To compare the safety and efficacy of a further attenuated measles vaccine (without serum) against the original vaccine (with serum).
- To evaluate the serological response and reaction severity of the new vaccine formulation.
Main Methods:
- A comparative study was conducted evaluating two measles vaccine formulations.
- One formulation involved the original Enders vaccine combined with immune serum.
- The second formulation utilized a further attenuated measles vaccine administered without immune serum.
Main Results:
- The further attenuated vaccine without serum demonstrated significantly fewer and less severe reactions compared to the original vaccine with serum.
- The new vaccine formulation elicited a satisfactory serological response, indicating effective immunity.
- The findings suggest improved tolerability and a viable alternative for measles vaccination.
Conclusions:
- A further attenuated measles vaccine, administered without immune serum, is a safe and effective option for children.
- This improved vaccine has the potential to overcome the limitations of the original vaccine, particularly in resource-limited settings.
- Facilitating large-scale immunization programs in West Africa is a key implication of this research for measles control.
Related Concept Videos
Vaccinations
Smallpox
Poliomyelitis
Chickenpox
Microorganisms in Medicine and Therapeutics
Cross-reactivity

